Doximity Is Up 31% on an AI Upgrade-Has the Bull Case Truly Changed?

The rerating was driven by AI economics, not just hype

The market is moving faster than the filings do.

Heading into earnings, Doximity was still being discussed as a quietly discounted healthcare platform. After the print, that changed quickly. Shares jumped about 33% in the first full session as investors began valuing the company less like a mature digital-health name and more like a profitable business building a real AI layer into a specialized professional network.

What changed the valuation

The trigger was not AI rhetoric alone. Doximity reported roughly $156.6 million in revenue, held its profitability profile, and lifted its full-year revenue outlook to $671 million-$681 million. That helps explain the rerating: bulls are paying for a company that appears to be funding AI investment while still protecting margins.

The tension is that the income statement does not fully prove the AI case yet. Revenue grew about 7%, net income fell about 54%, and stock-based compensation reached 23% of revenue. At the same time, roughly 17% of tradable shares were sold short, so the squeeze likely added fuel to the move.

If AI revenue is still not fully captured in guidance, as analysts suggested, today's higher multiple could still look early. The risk is that investors have paid for later-stage AI economics in a business that is still transitioning.

Why the AI case looks more credible than a typical product launch

The rerating only works if AI becomes a margin-friendly upsell rather than a costly experiment. That shifts the central question from "Is the product impressive?" to "Can Doximity monetize more within an existing professional network without damaging the earnings engine?" The core business has at least shown it can still run profitably. Doximity produced roughly $156.6 million of revenue with a 48% adjusted EBITDA margin, even as net income fell to about $24.3 million from about $53.3 million a year earlier.

Revenue per search is the key operating claim

The most important management point was not the demo. It was the claim that AI Search is generating more than 10x as much revenue per search as it costs to operate. If that holds at scale, AI starts to look less like a feature and more like a monetizable layer on top of an existing user base.

That is the cleanest version of the bull case: existing customers use more AI, monetization per interaction is favorable, and infrastructure spend can be spread across a growing base. Doximity's recent update suggested meaningful AI revenue may still not be fully reflected in guidance, which is why the story feels more substantive than a standard product launch.

Pharma demand is the second lever

The pharma adjacency is the other part of the upside. Management said AI Search could expand Doximity's opportunity in healthcare and pharmaceutical advertising, and Canaccord specifically pointed to growing demand for Doximity's AI products, especially from pharmaceutical companies. That matters because pharma spend is not just added revenue; it could deepen monetization within the same workflow.

Analyst follow-through also makes the case more credible. Canaccord and BMO raised price targets after the print, citing growing demand for Doximity's AI products. More specifically, Canaccord said AI revenue could become a meaningful growth driver in the third quarter. Doximity also raised its full-year outlook to $671 million to $681 million, while analysts reportedly believe meaningful AI revenue still is not fully captured in that guidance.

The product story still has limits. The claim that Doximity's clinical AI posted a 4.8% error rate versus 13.6% for Anthropic's Fable 5 may help as a differentiation point, but it is not revenue proof. Until AI dollars show up more clearly in reported sales and margins, that promise belongs in the upside case, not the base case.

What could break the bull case over the next couple of quarters

A rally this sharp raises the bar for the next reports.

Doximity already ran into this problem once. In its prior reported quarter, the company delivered a Q4 CY2025 revenue beat and beat on non-GAAP profit, but still guided Q1 CY2026 revenue to $143.5 million, below analyst estimates of $151.3 million. The market punished that mismatch because a guidance miss can matter more than a headline beat when investors are testing whether growth is durable.

What investors need to see next

The bear case is not that Doximity lacks a real AI story. It is that the rerating may be outrunning what one or two quarters can support. Bulls now need cleaner proof than a strong session and upbeat commentary. They need another beat-and-raise pattern, clearer AI revenue in reported sales, and evidence that pharma demand is converting into near-term cash rather than staying mostly prospective.

That timing issue matters. Management and at least one analyst have pointed to growing demand for Doximity's AI products, especially from pharmaceutical companies, and Canaccord expects AI revenue to become a meaningful growth driver in the third quarter. But if pharma budget cycles slip again, the income statement can stay softer than the stock already assumes.

A 48% adjusted EBITDA margin is strong, but net income fell about 54%. That gap is the warning light. If investors shift focus from AI optionality to bottom-line execution, one soft quarter can undo a lot of rerating.

Watch these signals over the next one to two quarters: - Another forward guidance beat, not just a solid quarter. - AI revenue showing up more clearly in reported sales rather than only in usage metrics. - No repeat of the prior pattern in which a beat was followed by below-consensus next-quarter revenue guidance.

The right lens is simple: if the next print adds proof, the bull case can keep building. If it adds only momentum, this becomes a momentum trade, and those can unwind quickly when 17% of tradable shares were sold short and the squeeze runs out of fresh fuel.